Mechanisms and therapeutic implications of hypermutation in gliomas

Journal: Nature

Published: 2020-04-15

DOI: 10.1038/s41586-020-2209-9

Affiliations: 41

Authors: 78

Go to article
Institutions Share
Dana-Farber Cancer Institute (DFCI), United States of America (USA) 0.26
Brain and Spine Institute (ICM), France 0.14
AP-HP Pitié-Salpêtrière Hospital - Charles-Foix, France 0.13
Brigham and Women's Hospital (BWH), United States of America (USA) 0.11
Foundation Medicine, Inc., United States of America (USA) 0.06
Broad Institute of MIT and Harvard, United States of America (USA) 0.06
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, United States of America (USA) 0.04
Harvard University, United States of America (USA) 0.04
Boston Children's Hospital (BCH), United States of America (USA) 0.04
Tumour Immunology and Anti-Cancer Immunotherapy Unit, France 0.03
Cochin Hospital, France 0.01
Case Western Reserve University (CWRU), United States of America (USA) 0.01
OSU Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), United States of America (USA) 0.01
European Bioinformatics Institute (EMBL-EBI), United Kingdom (UK) 0.01
Wake Forest Baptist Health, WFU, United States of America (USA) 0.01
Institute Gustave-Roussy (IGR), France 0.01
Imagerie par Résonance Magnétique Médicale et Multi-Modalités (IR4M), France 0.01
Saint Antoine Research Center (CRSA), France 0.01
Ligue Contre Le Cancer, France 0.01
Ludwig Center at Harvard Medical School, United States of America (USA) 0

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER